Study Evaluating the Safety, Tolerability and Efficacy of PBT2 in Patients With Early Alzheimer's Disease
NCT ID: NCT00471211
Last Updated: 2008-01-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
80 participants
INTERVENTIONAL
2006-12-31
2007-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease
NCT07094516
Study of LM11A-31-BHS in Mild-moderate AD Patients
NCT03069014
A Safety and Tolerability Study of JNJ-54861911 in Participants With Early Alzheimer's Disease
NCT02260674
Multiple IV Dose Study Of PF-04360365 In Patients With Mild To Moderate Alzheimer's Disease
NCT00722046
A Safety and Tolerability Evaluation of Two 10-Week Dose Regimens of Orally-Administered PF-04494700 in Alzheimer's Patients
NCT00141661
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PBT2
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* stable dose of acetylcholinesterase inhibitor
* community dwelling
* stable medical condition
Exclusion Criteria
* recurrent major psychiatric disorder
* treatment with memantine
56 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Prana Biotechnology Limited
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Lars Lannfelt, Professor
Role: PRINCIPAL_INVESTIGATOR
Uppsala University Hospital, Sweden
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sydney, New South Wales, Australia
Sydney, New South Wales, Australia
Adelaide, South Australia, Australia
Melbourne, Victoria, Australia
Melbourne, Victoria, Australia
Melbourne, Victoria, Australia
Melbourne, Victoria, Australia
Falköping, , Sweden
Kalix, , Sweden
Kalmar, , Sweden
Lund, , Sweden
Malmo, , Sweden
Stockholm, , Sweden
Umeå, , Sweden
Uppsala, , Sweden
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Lannfelt L, Blennow K, Zetterberg H, Batsman S, Ames D, Harrison J, Masters CL, Targum S, Bush AI, Murdoch R, Wilson J, Ritchie CW; PBT2-201-EURO study group. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2008 Sep;7(9):779-86. doi: 10.1016/S1474-4422(08)70167-4. Epub 2008 Jul 30.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PBT2-201
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.